Year End Report 2015
Fourth quarter 2015 for the Group compared to 2014
» Net sales amounted to SEK 375,368 (54,541).
» Other operating income amounted to SEK 1,849,848 (997,520).
» Income after financial items amounted to SEK -14,148,843 (-8,055,327).
» Earnings per share (weighted average) amounted to SEK -0.89 (-0.73).
Twelve months 2015 for the Group compared to 2014
» Net sales amounted to SEK 1,016,462 (173,026).
» Other operating income amounted to SEK 5,628,598 (2,166,468).
» Income after financial items amounted to SEK -43,974,662 (-32,914,421).
» Earnings per share (weighted average) amounted to SEK -3,52 (-2,98).
» Equity per share amounted to SEK 6,89 (4,88).
Significant events during the fourth quarter
» First two surgeries with Episurf’s most recent product, the Episealer® Twin, were performed in Germany with satisfactory results.
» Episurf’s First Surgery in Switzerland was successfully completed.
» Episurf Medical appointed a seasoned Clinical Advisory Board comprised of European medical industry Key Opinion Leaders.
» Episurf Medical received CE mark for its fourth product, the Epiguide® MOS.
Significant events after year end
» Episurf Medical received CE mark for its fifth product, EpioscopyTM Damage Assessment Tool.
» Episurf Medical launched German website and increased marketing efforts in the region.
» Episurf Medical announced the 100 account milestone was reached.
» Episurf scientific abstract submission was granted a poster presentation at ESSKA.
» The 4th German sales person was hired.
» The 2nd Nordic Sales person was hired.
» Spire Hospital UK approved Episealer® as a new clinical procedure for private insurance patients.
Extract from CEO Rosemary Cunningham Thomas CEO statement:
» The company has transitioned from an engineering tech start up into a commercially driven medical technology company uniquely positioned to become the leading intelligent implant company for joint injuries.
» Revenues from implant sales exceeded 1 million SEK, representing an increase of 487% on previous year.
» By the end of 2015, Episurf had 73 implants in patients across Europe, representing an increase of 232% compared with 2014.
» To date, 27 orthopedic surgeons in 10 European countries have performed surgeries using an Episealer®. Out of those surgeons, 56% have already performed their second Episealer® surgery and 44% have performed their third surgery using an Episealer®.
The complete Year End Report is attached to this press release and is available on the company's website.
The information in this Interim Report is such that Episurf Medical AB is required to disclose in accordance with the Securities Markets Act and/or the Financial Instruments Trading Act.
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are in development for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system will enable implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention.
Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com. The information in this press release is such that Episurf Medical AB is required to disclose in accordance with the Securities Markets Act and/or the Financial Instruments Trading Act.
For more information, please contact:
Rosemary Cunningham Thomas, CEO, Episurf Medical
Tel: +46 (0) 70-7655892
Tel: +44 (0) 7803-753603
E-mail: rosemary@episurf.com